🔴 Absci is trading 9.84% down in pre-market after second-quarter revenue and loss missed expectations

Absci is trading at $8.48 (-9.84%) in pre-market after its August 11, 2026 second-quarter results missed analyst expectations.

• Revenue was $0.3 million versus $1.01 million expected, while adjusted loss reached $0.21 per share versus $0.19 expected.
• The $100 million financing, including $40 million from Eli Lilly, extended liquidity into the second half of 2028, but weak revenue and ongoing losses appear to outweigh that benefit.